N. Gupta
- The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmaticsBy M. Solèr, J. Matz, R. Townley, R. Buhl, J. O'Brien, H. Fox, J. Thirlwell, N. Gupta and G. Della CioppaM. SolèrJ. MatzR. TownleyR. BuhlJ. O'BrienH. FoxJ. ThirlwellN. Gupta
- An unusual case of mediastinal mass due to Fonsecaea pedrosoiBy N. Singh, R. Agarwal, D. Gupta, M. R. Shivaprakash and A. ChakrabartiN. SinghR. AgarwalD. GuptaM. R. Shivaprakash
- Improvement with long-term itraconazole therapy for Fonsecaea pedrosoi-related mediastinal phaeohyphomycosisBy N. Singh, R. Agarwal and D. GuptaN. SinghR. Agarwal
- Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in IndiaBy R. Singla, J.A. Caminero, A. Jaiswal, N. Singla, S. Gupta, R.K. Bali and D. BeheraR. SinglaJ.A. CamineroA. JaiswalN. SinglaS. GuptaR.K. BaliD. Behera
- Linezolid, an effective, safe and cheap drug in MDR-TB treatment failure patients in IndiaBy R. Singla, J.A. Caminero, A. Jaiswal, N. Singla, S. Gupta, R.K. Bali and D. BeheraArticle | Published in 2011 in European Respiratory JournalR. SinglaJ.A. CamineroA. JaiswalN. SinglaS. GuptaR.K. BaliD. Behera
- Pharmacokinetic (PK) analysis of fluticasone furoate (FF), umeclidinium (UMEC) and vilanterol (VI) following triple therapy in healthy subjectsBy A. Allen, A. Henderson, A. Gupta, J. Renaux and N. BrealeyA. Allen1Clinical Pharmacology Modelling and Simulation Department, GlaxoSmithKline, Stevenage, United KingdomA. Henderson1Clinical Pharmacology Modelling and Simulation Department, GlaxoSmithKline, Stevenage, United KingdomA. Gupta1Clinical Pharmacology Modelling and Simulation Department, GlaxoSmithKline, Stevenage, United KingdomJ. Renaux1Clinical Pharmacology Modelling and Simulation Department, GlaxoSmithKline, Stevenage, United KingdomN. Brealey1Clinical Pharmacology Modelling and Simulation Department, GlaxoSmithKline, Stevenage, United Kingdom
- Pharmacokinetic (PK) analysis of fluticasone furoate (FF), umeclidinium (UMEC) and vilanterol (VI) following triple therapy at two UMEC doses in healthy subjectsBy A. Henderson, A. Allen, A. Gupta, J. Renaux and N. BrealeyA. Henderson1Clinical Pharmacology Science and Study Operations, GlaxoSmithKline, Stevenage, United KingdomA. Allen2Clinical Pharmacology Modelling and Simulation Department, GlaxoSmithKline, Stevenage, United KingdomA. Gupta3Quantitative Sciences India, GlaxoSmithKline, Bangalore, IndiaJ. Renaux4Respiratory Clinical Pharmacology Science and Study Operations, GlaxoSmithKline, Uxbridge, United KingdomN. Brealey5Respiratory Medicines Development Centre, GlaxoSmithKline, Uxbridge, United Kingdom
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.